CoChat

CYP Induction-Mediated Drug Interactions: in Vitro Assessment and Clinical Implications

Lin, Jiunn H. · 2006 · Pharmaceutical Research

The DOI matches its Crossref record; 256 of the 257 references it cites were found in a registry or an index.

Abstract

Cytochrome P450 (CYP) induction-mediated interaction is one of the major concerns in clinical practice and for the pharmaceutical industry. There are two major issues associated with CYP induction: a reduction in therapeutic efficacy of comedications and an induction in reactive metabolite-induced toxicity. Because CYP induction is a metabolic liability in drug therapy, it is highly desirable to develop new drug candidates that are not potent CYP inducer to avoid the potential of CYP induction-mediated drug interactions. For this reason, today, many drug companies routinely include the assessment of CYP induction at the stage of drug discovery as part of the selection processes of new drug candidates for further clinical development. The purpose of this article is to review the molecular mechanisms of CYP induction and the clinical implications, including pharmacokinetic and pharmacodynamic consequences. In addition, factors that affect the degree of CYP induction and extrapolation of in vitro CYP induction data to in vivo situations will also be discussed. Finally, assessment of the potential of CYP induction at the drug discovery and development stage will be discussed.

Overview

Integrity signals

Registry

Crossref · 10.1007/s11095-006-0277-7

Cites

256 of 256 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Items 201–256 of 256

Research works printed but not linked: 27

  1. H. V. Gelboin, 1980, Pharmacol. Rev., 60, 1107
  2. J. M. Silva, 1998, Drug Metab. Dispos., 26, 490
  3. W. El-Sankary, 2001, Drug Metab. Dispos., 29, 1499
  4. R. C. Pollenz, 1994, Mol. Pharmacol., 45, 428
  5. J.-M. Passcussi, 2000, Mol. Pharmacol., 58, 1441, 10.1124/mol.58.6.1441 · doi:10.1124/mol.58.6.1441 · Paper page
  6. T. A. Kocarek, 1995, Drug Metab. Dispos., 23, 415
  7. S. M. Fontaine, 2001, Drug Metab. Dispos., 29, 1236
  8. J. L. Barwick, 1996, Mol. Pharmacol., 50, 10
  9. T. Shimada, 1994, J. Pharmacol. Exp. Ther., 270, 414
  10. K. E. Thummel, 1994, J. Pharmacol. Exp. Ther., 271, 557
  11. M. F. Paine, 1997, J. Pharmacol. Exp. Ther., 283, 1552
  12. E. T. Morgan, 2001, Drug Metab. Dispos., 29, 207
  13. T. K. Chang, 1997, Cancer Res., 57, 1946
  14. A. Poland, 1990, Mol. Pharmacol., 38, 306
  15. G. R. Wilkinson, 1987, Pharmacol. Rev., 39, 1
  16. N. Holtbecker, 1996, Drug Metab. Dispos., 24, 1121
  17. S. Gerbal-Chaloin, 2001, Drug Metab. Dispos., 29, 242
  18. L. Drocourt, 2001, Drug Metab. Dispos., 29, 1325
  19. S. C. Nallami, 2003, Epilepsia, 44, 1428
  20. I. Waziers de, 1990, J. Pharmacol. Exp. Ther., 253, 387
  21. R. A. O'Reilly, 1987, Adv. Exp. Med. Biol., 214, 205
  22. Y. Caraco, 1997, J. Pharmacol. Exp. Ther., 281, 330
  23. W. D. Fiske, D. Mayers, and K. Wagner. Pharmacokinetics of DMP 266 and indinavir multiple oral doses in HIV-1 infected individuals [abstract no. 568]. 4th Conference on Retroviruses and Opportunistic Infections. 1996, Jan 28–Feb 1. Washington, DC.
  24. A. H. Conney, 2003, Cancer Res., 63, 7005
  25. A. Cantani, 2005, Eur. Rev. Med. Pharmacol. Sci., 9, 23
  26. M. Morimoto, 1995, Hepatology, 21, 1610
  27. E. L. LeCluyse, 1996, Model Systems for Biopharmaceutical Assessment of Drug Absorption and Metabolism, 125

Cited by

See all 283

Metadata

Authors
Lin, J. H.
Affiliations
Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Corresponding author
Lin, Jiunn H.
Venue
Pharmaceutical Research
Published
2006-05-26
Volume
23
Issue
6
Pages
1089-1116
ISSN
  • 0724-8741 (ISSN-L)
  • 1573-904X
OpenAlex
W1997271604
Cited by
264
References
257
Citations by year
2026: 2 · 2025: 5 · 2024: 7 · 2023: 3 · 2022: 10 · 2021: 11 · 2020: 13 · 2019: 7 · 2018: 8 · 2017: 9 · 2016: 11 · 2015: 13 · 2014: 11 · 2013: 15 · 2012: 22
FWCI
3.47
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Pharmaceutical Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
Keywords
cytochrome P450 induction, drug interactions, CYP inducers, in vitro-in vivo extrapolation, pharmacokinetics, pharmacodynamics, drug discovery, drug development, treatment efficacy
MeSH terms
Pregnane X Receptor, Constitutive Androstane Receptor, Animals, Drug Interactions, Enzyme Induction, Humans, Liver, Pharmacokinetics, Pharmacology, Receptors, Steroid, Species Specificity, Transcription Factors, Genetic Variation, Drug Design, Receptors, Cytoplasmic and Nuclear, Receptors, Aryl Hydrocarbon, Cytochrome P-450 CYP2B1, Cytochrome P-450 CYP2E1, Receptor Cross-Talk, Cytochrome P-450 CYP3A

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.